A priority goal for next-generation COVID-19 vaccines is to reduce infection with and transmission of SARS-CoV-2 via the respiratory route, while maintaining or enhancing protection against symptomatic and severe disease. Utilization of mucosal vaccination to elicit robust mucosal immunity in the respiratory tract is a logical approach to achieving these goals.
Read More
View All News
USSF collaboration (VaxForm) amongst the select few on list of nextgen SARS-CoV-2 mucosal vaccine candidates in use or in clinical development.
April 12, 2023
About the Author
Written by the GamePlanX Network of Experts - https://gameplanx.com, a multidisciplinary team specializing in outcome‑driven strategic growth, regulatory‑compliant digital marketing, and AI‑enabled operational optimization across industries. For this article, the GamePlanX team contributes expertise specifically relevant to USSF’s cGMP pharmaceutical manufacturing operations, botanical injectables, and clinical education initiatives.
